Implications of Treatment That Target Protective Mechanisms Against Diabetic Nephropathy

Seminars in Nephrology

Volumn 32, Issue 5, 2012, Pages 471-478

  Mima, Akira ^a   Qi, Weier ^a   King, George L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIOXIDANT; ASCORBIC ACID; BARDOXOLONE; CAPTOPRIL; CELECOXIB; CREATININE; DIPYRIDAMOLE; EPALRESTAT; FG 3019; GLUCAGON LIKE PEPTIDE 1; INSULIN; LISINOPRIL; LOSARTAN; METALLOPROTEINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; PARICALCITOL; PENTOXIFYLLINE; PLACEBO; PYRIDOXAMINE; RUBOXISTAURIN; SPIRONOLACTONE; TOLRESTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VITAMIN D; XL 784;

ALBUMINURIA; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DNA DAMAGE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; URINE LEVEL;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; INSULIN; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867377246     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.07.010     Document Type: Article

References (67)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
3. Nobakht N., Kamgar M., Rastogi A., Schrier R.W. Limitations of angiotensin inhibition. Nat Rev Nephrol 2011, 7:356-359.
4. Keenan H.A., Costacou T., Sun J.K., et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care 2007, 30:1995-1997.
5. Sun J.K., Keenan H.A., Cavallerano J.D., et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study. Diabetes Care 2011, 34:968-974.
6. Geraldes P., Hiraoka-Yamamoto J., Matsumoto M., et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009, 15:1298-1306.
7. Rask-Madsen C., King G.L. Kidney complications: factors that protect the diabetic vasculature. Nat Med 2010, 16:40-41.
8. Wendt T.M., Tanji N., Guo J., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
9. Bolton W.K., Cattran D.C., Williams M.E., et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004, 24:32-40.
10. Tilton R.G., Chang K., Hasan K.S., et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993, 42:221-232.
11. Suji G., Sivakami S. DNA damage by free radical production by aminoguanidine. Ann N Y Acad Sci 2006, 1067:191-199.
12. Chetyrkin S.V., Mathis M.E., Ham A.J., et al. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Free Radic Biol Med 2008, 44:1276-1285.
13. Onorato J.M., Jenkins A.J., Thorpe S.R., Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000, 275:21177-21184.
14. Williams M.E., Bolton W.K., Khalifah R.G., et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007, 27:605-614.
15. Lewis E.J., Greene T., Spitalewiz S., et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2011, 23:131-136.
16. Passariello N., Sepe J., Marrazzo G., et al. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 1993, 16:789-795.
17. Iso K., Tada H., Kuboki K., Inokuchi T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in type 2 diabetic patients. J Diabetes Complications 2001, 15:241-244.
18. Inoguchi T., Sonta T., Tsubouchi H., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003, 14(Suppl 3):S227-S232.
19. Koya D., Lee I.K., Ishii H., Kanoh H., King G.L. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 1997, 8:426-435.
20. Beckman J.A., Goldfine A.B., Gordon M.B., Creager M.A. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001, 103:1618-1623.
21. Pergola P.E., Raskin P., Toto R.D., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011, 365:327-336.
22. Yates M.S., Tauchi M., Katsuoka F., et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007, 6:154-162.
23. Rodriguez-Iturbe B., Pons H., Herrera-Acosta J., Johnson R.J. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 2001, 59:1626-1640.
24. Blakytny R., Harding J.J. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res 1992, 54:509-518.
25. Hopper A.H., Tindall H., Davies J.A. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy. Nephrol Dial Transplant 1989, 4:140-143.
26. Cheng H.F., Wang C.J., Moeckel G.W., et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002, 62:929-939.
27. Sinsakul M., Sika M., Rodby R., et al. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Am J Kidney Dis 2007, 50:946-951.
28. Turgut F., Bolton W.K. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010, 55:928-940.
29. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990, 172:391-394.
30. Harmankaya O., Seber S., Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 2003, 25:465-470.
31. Navarro J.F., Mora C., Muros M., Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005, 16:2119-2126.
32. Chow F.Y., Nikolic-Paterson D.J., Ozols E., et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
33. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y., et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
34. Adler S.G., Schwartz S., Williams M.E., et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010, 5:1420-1428.
35. Tan S.M., Zhang Y., Cox A.J., Kelly D.J., Qi W. Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy. Nephrol Dial Transplant 2011, 26:100-110.
36. Williams J.M., Zhang J., North P., et al. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 2011, 300:F983-F998.
37. Mehdi U.F., Adams-Huet B., Raskin P., Vega G.L., Toto R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
38. de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricarcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
39. Perkins B.A., Ficociello L.H., Silva K.H., et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285-2293.
40. Koya D., Jirousek M.R., Lin Y.W., et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997, 100:115-126.
41. Mima A., Ohshiro Y., Kitada M., et al. Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int 2011, 79:883-896.
42. Ohshiro Y., Ma R.C., Yasuda Y., et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 2006, 55:3112-3120.
43. Gilbert R.E., Kim S.A., Tuttle K.R., et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 2007, 30:995-996.
44. Kang D.H., Joly A.H., Oh S.W., et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001, 12:1434-1447.
45. Naruse K., Rask-Madsen C., Takahara N., et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 2006, 55:691-698.
46. Jiang Z.Y., Lin Y.W., Clemont A., et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999, 104:447-457.
47. Cusi K., Maezono K., Osman A., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311-320.
48. He Z., Opland D.M., Way K.J., et al. Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler Thromb Vasc Biol 2006, 26:787-793.
49. Vicent D., Ilany J., Kondo T., et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 2003, 111:1373-1380.
50. Wolk R., Smith W.B., Neutel J.M., et al. Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension 2009, 53:1091-1097.
51. Welsh G.I., Hale L.J., Eremina V., et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010, 12:329-340.
52. Nicosia R.F., Nicosia S.V., Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994, 145:1023-1029.
53. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30336-30343.
54. Sison K., Eremina V., Baelde H., et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2011, 21:1691-1701.
55. Ziyadeh F.N. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 2008, 82(Suppl 1):S38-S41.
56. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707-716.
57. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
58. Fulcher C.A., Gardiner J.E., Griffin J.H., Zimmerman T.S. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984, 63:486-489.
59. Hafer-Macko C.E., Ivey F.M., Gyure K.A., Sorkin J.D., Macko R.F. Thrombomodulin deficiency in human diabetic nerve microvasculature. Diabetes 2002, 51:1957-1963.
60. Isermann B., Vinnikov I.A., Madhusudhan T., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.
61. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
62. Park C.W., Kim H.W., Ko S.H., et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007, 18:1227-1238.
63. Kodera R., Shikata K., Kataoka H.U., et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011, 54:965-978.
64. Erdogdu O., Nathanson D., Sjoholm A., Nystrom T., Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010, 325:26-35.
65. Tuttle K.R., Bakris G.L., Toto R.D., et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005, 28:2686-2690.
66. Gaede P., Poulsen H.E., Parving H.H., Pedersen O. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 2001, 18:756-760.
67. Guerrero-Romero F., Rodriguez-Moran M., Paniagua-Sierra J.R., et al. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 1995, 43:116-121.